WINSTON-SALEM, N.C., Oct. 25 /PRNewswire-FirstCall/ -- Targacept, Inc. (Nasdaq: TRGT - News), a clinical-stage biopharmaceutical company developing a new class of drugs known as NNR Therapeutics(TM), today announced that J. Donald deBethizy, Ph.D., President and Chief Executive Officer, will be presenting at two upcoming investor conferences:
